MannKind Corp
Company Profile
Business description
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Contact
1 Casper Street
DanburyCT06810
USAT: +1 818 661-5000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
592
Stocks News & Analysis
stocks
Wide moat airport share steps up its investments
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,300.80 | 6.70 | -0.07% |
| CAC 40 | 8,484.43 | 31.34 | 0.37% |
| DAX 40 | 26,136.56 | 153.52 | 0.59% |
| Dow JONES (US) | 53,277.01 | 517.80 | 0.98% |
| FTSE 100 | 10,816.56 | 68.40 | 0.64% |
| HKSE | 26,009.46 | 310.97 | 1.21% |
| NASDAQ | 26,180.46 | 113.29 | 0.43% |
| Nikkei 225 | 66,008.98 | 7.38 | -0.01% |
| NZX 50 Index | 13,947.41 | 25.25 | -0.18% |
| S&P 500 | 7,674.37 | 33.21 | 0.43% |
| S&P/ASX 200 | 9,088.90 | 4.30 | -0.05% |
| SSE Composite Index | 3,905.10 | 0.11 | -0.00% |